Tan, Antoinette R. http://orcid.org/0000-0002-7895-7000
Chan, Nancy
Kiesel, Brian F.
Stein, Mark N.
Moss, Rebecca A.
Malhotra, Jyoti
Aisner, Joseph
Shah, Mansi
Gounder, Murugesan
Lin, Hongxia
Kane, Michael P.
Lin, Yong
Ji, Jiuping
Chen, Alice
Beumer, Jan H.
Mehnert, Janice M.
Funding for this research was provided by:
National Cancer Institute (U01-CA-132194-01, UM1-CA-186716, UM1-CA-186690, U01-CA099168, R50CA211241)
UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility (P30-CA47904)
Article History
Received: 3 April 2021
Accepted: 27 August 2021
First Online: 20 October 2021
Declarations
:
: A. Tan has received research grants from Arvinas, Deciphera, Daiichi-Sankyo, Genentech, Merck, and Pfizer; advisory board member/paid consultant for Athenex, AstraZeneca, Eisai, G1 Therapeutics, Novartis, and Immunomedics. M. Stein has received research grants from Merck, Exelixis, Oncoceutics, Janssen, Medivation/Astellas, Advaxis, Suzhou Kintor, Harpoon, Bristol-Meyers Squibb, Genocea, Eli Lilly, Seattle Genetics and Xencor. R. Moss is an employee for Bristol-Myers Squibb. J. Malhotra has received commercial research grants from AstraZeneca, Beyond Spring, Bristol-Myers Squibb, Biohaven and Pfizer. J. Aisner is on the DMC for EMD Serono. J. Mehnert has received research grants from Merck, EMD Serono, Pfizer, Genentech, Amgen, Boehringer Ingelheim, Array BioPharma, Immunocore, AstraZeneca, Incyte, Macrogenics, Bristol-Myers Squibb, Novartis, and Polynoma. No potential conflicts of interest were disclosed by the other authors.